Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. Issue 8 (25th August 2020)

• Record Type: Journal Article
• Authors: Psotka, Mitchell A.; Fiuzat, Mona; Solomon, Scott D.; Chauhan, Cynthia; Felker, G. Michael; Butler, Javed; Teerlink, John R.; Sinha, Shashank S.; O'Connor, Christopher M.; Konstam, Marvin A.
• Is Part Of: Circulation. Volume 142:Issue 8(2020)
• Publication Date: 2020-08-25
• Subjects: cardiovascular diseases -- drug prescriptions -- health insurance -- heart failure -- prior authorization; Blood -- Circulation -- Periodicals; Cardiovascular system -- Periodicals; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; Blood Circulation; Cardiovascular System; Vascular Diseases; 616.1
• DOI: 10.1161/CIRCULATIONAHA.119.044976
• Languages: English
• ISSNs: 0009-7322

Abstract

Abstract : Patient access to a drug after US regulatory approval is controlled by complex interactions between governmental and third-party payers, pharmacy benefit managers, distributers, manufacturers, health systems, and pharmacies that together mediate the receipt of goods by patients after prescription by clinicians. Recent medication approvals highlight why and how the distribution of clinically beneficial novel therapies is controlled. Although imposed limitations on availability may be rational considering the fiduciary responsibilities of payers and escalating spending on health care and pharmaceuticals, transparency and communication are lacking, and some utilization management may disproportionately affect vulnerable populations. Analysis of the current health insurance landscape suggests mechanisms by which patient access to appropriate medications can be improved and patient and clinician frustration reduced while acknowledging the financial realities of the pharmaceutical marketplace. We propose creation of a shared, standardized, and transparent process for coverage decisions that minimizes administrative barriers and is defensible on the basis of clinical and cost-effectiveness evidence. These reforms would benefit patients and improve the efficiency of the pharmaceutical system.